ISSN (Print): 2374-1996

ISSN (Online): 2374-2003


Editor-in-chief: Jean Rommelaere

You are here

Currrent Issue: Volume 4, Number 3, 2016


Clinical Application of Laparoscopy in Radical Operation of Rectal Cancer

1Department of general surgery, Xiaogan Central Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China

2Medical College of Wuhan University of Science and Technology, Wuhan, China

Journal of Cancer Research and Treatment. 2016, 4(3), 49-51
doi: 10.12691/jcrt-4-3-3
Copyright © 2016 Science and Education Publishing

Cite this paper:
Guangwei Gong, Shengwen Li, Li Luo, Dan Zhao, Jun Wei, Yue Qiu, Lei Ji, Kun Yang, Xiongshan Shen, Weimin Li, Jinjun Li. Clinical Application of Laparoscopy in Radical Operation of Rectal Cancer. Journal of Cancer Research and Treatment. 2016; 4(3):49-51. doi: 10.12691/jcrt-4-3-3.

Correspondence to: Jinjun  Li, Medical College of Wuhan University of Science and Technology, Wuhan, China. Email:


Objective: Analyze the clinical value of laparoscopic used in the colorectal cancer surgery. Methods: A total number of 371 clinical cases, from January 2012 to October 2014 in our hospital, were analyzed which covered 198 patients underwent the laparoscopy in radical resection and 173 cases in open radical resection. A retrospective analysis was proceeded by comparing the general information, surgery performance, pathologic data, postoperative recovery and complicetions as well as long-term survival to investigate the diversity of immediate and long-term clinical outcomes of laparoscopic radical operation. Results: All patients have successfully completed the surgery, which includes 198 cases of laparoscopic rectal resection, 173 cases in open radical resection. There were no statistically significance differences between gender, age, height, BMI, staging and associated with other diseases in two groups. The operative time of rectal resection under the Laparoscopic was shorter than open radical resection (120±30minvs 105±39min), with no statistical significance(P>0.05).In the laparoscopy surgery, the amount of bleeding is less than open surgery (50±20ml VS 200±25ml), and the difference was statistically significant. In the laparoscopy surgery, the length of incision is shorter than open surgery (5.1±0.23cm VS 13.5±1.34cm), and the difference was statistically significant. The hospitalization length in laparoscopy surgery and open surgery was significant difference (P<0.01). Conclusion: In contrast to open surgery group, the laparoscopy surgery group expericenced less bleeding, shorter incisionand hospitalization length. The incident rate of perioperation complications in laparoscopy surgery and open surgery groups were not significant different. The colorectal cancer resection with laparoscopic has less trauma and can recover quickly, so it can achieve the same radical effect just like laparotomy and worth to be promoted in the Clinical application.



[1]  Huang C,Shen JC, Zhang J,et al. Clinical comparison of laparoscopy vs open surgery in a radical operation for rectal cancer:A retrospective case control study[J].World J Gastroenterology,2015,21(48):13532-13541.
[2]  Guo C, Zhang Z, Ren B,et al.Comparison of the long-term outcomes of patients who underwent laparoscopic versus open surgery for rectal cancer[J].J BUON,2015 20(6):1440-1446.
[3]  Pascual M, Salvans S, Pera M,et al. Laparoscopic colorectal surgery: Current status and implementation of the latest technological innovations[J]. World J Gastroenterol, 2016,22(2): 718-726.
[4]  Vennix S, Pelzers L, Bouvy N,et al.Laparoscopic versus open total mesorectal excision for rectal cancer[J].Cochrane Database Syst Rev,15(4):pub3.
[5]  Zaharie F, Ciorogar G, Zaharie R,et al.Laparoscopic rectal resectionversus conventional open approach for rectal cancer -a4-year experience of a single center[J].J BUON,2015,20(6):1447-1455.
Show More References
[6]  Buia A, Stockhausen F, Hanisch E.Laparoscopic surgery: A qualified systematic review[J].2015,5(4):238-254.
[7]  Nakamura H, Uehara K, Arimoto A,et al.The feasibility of laparoscopic extended pelvic surgery for rectal cancer[J].Surg Today,2015, 22(10): p1-7.
[8]  Aziz O, Constantinides V,TEKKIS PP, et al. Laparoscopic versus open surgery for rectal cancer: ameta-analysis [J].Ann Surg Oncol,2006,13(3):413-424.
[9]  Bruch HP, Esnaashari H, Schwandner O .Current status of laparoscopic therapy of colorectal[J].Dig Dis,2005, 23(2): 127-134.
[10]  Park IJ, Choi CS, Lim KH, et al. Laparoscopic resection of extraperitioneal rectal cancer: a comparative analysis with open resection[J].Surg Endosc,2009,23(8):1818-1824.
[11]  Braga M,FrassonM,VignaliA,etal.Laparoscopic resection in rectal cancer patients: outcome and cost-benefit analysis[J].Dis Colon Rectum,2007,50(4):464-471.
[12]  Katsuno H, Shiomi A, Ito M,et al.Comparison of symptomatic anastomotic leakage following laparoscopic and open low anterior resection forrectal cancer: a propensity score matching analysis of 1014 consecutive patients.Surg Endosc, 2015, 20(10): p1-9.
[13]  Baik SH, Ginchermaa M, Mutch MG. Laparoscopic vs open resection for patients with rectal cancer: comparison of perioperative outcomes and long-term survival[J].Diseases of the Colon & Rectum,2011,(01):6-14.
[14]  Tao, Sun Jing, Qiu Zhengjun. “The Long-term efficacy of laparoscopic and open surgery for colon cancer” [J].Journalof Fudan University (Medical Sciences). 2011, (03): 211-215.
Show Less References


Adipocyte-fatty Acid Binding Protein is Associated with Clinical Stage and Inflammatory Markers in Head and Neck Cancer Patients

1Radiation Sciences Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

2Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

Journal of Cancer Research and Treatment. 2016, 4(3), 41-48
doi: 10.12691/jcrt-4-3-2
Copyright © 2016 Science and Education Publishing

Cite this paper:
Sanaa A. El-Benhawy, Heba G. El-Sheredy. Adipocyte-fatty Acid Binding Protein is Associated with Clinical Stage and Inflammatory Markers in Head and Neck Cancer Patients. Journal of Cancer Research and Treatment. 2016; 4(3):41-48. doi: 10.12691/jcrt-4-3-2.

Correspondence to: Sanaa  A. El-Benhawy, Radiation Sciences Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. Email:


Background: Head and neck carcinomas are the fifth most common cancer worldwide. Squamous cell carcinoma of the head and neck (HNSCC) is a highly heterogeneous tumor. Additional clinical and biological factors are needed to improve tumor diagnosis and to identify subsets of patients with unfavorable outcome. Several recent studies showed that cancer cells stimulate lipid metabolism during tumor progression. Studies have revealed the involvement of fatty acid binding proteins (FABPs) expression in the pathology of different diseases including malignant neoplasms. It has been suggested that the immune changes occurring in the tumour environment determine its aggressive behavior, these changes may affect the prognosis and treatment outcomes in patients with cancer. The tumor necrosis factor (TNF-α) is a proinflammatory cytokine that expressed in HNSCC has a possible role in cancer invasiveness and the risk of metastases. C-reactive protein (C-RP) is an acute-phase protein that increases in acute, chronic inflammations, infections and tissue damages. It has been suggested that C-RP also is elevated in cancers. Objective: The aim of this study was to determine whether the plasma levels of A-FABP are linked to head and neck cancer, inflammatory markers (TNF-α and C-RP) and tumor characteristics. Subjects and Methods: The present study was conducted on 50 healthy individuals and 50 newly diagnosed patients with histologically confirmed HNSCC that accepted to participate. Patients with distant metastases at time of diagnosis, hepatic insufficiency, active autoimmune or coexisting infectious disease were excluded. The study included HNSCC patients with tumours ranged from stage I-IVA (cT1-4a, N0-2, M0). Age, sex, date of diagnosis, tumor site, grade, TNM stage and treatment were recorded. Results: Statistical analysis of the results showed that the mean values of plasma A-FABP, TNF-α and C-RP in HNSCC patients before treatment were significantly higher than that in control group. The plasma levels of the three biomarkers were significantly decreased after treatment than their corresponding values before treatment and plasma C-RP levels became within the normal control values. The risk for head and neck cancer is significantly increased in higher plasma A-FABP group compared with lower levels group. A significant positive correlation was found between plasma A-FABP and both TNF-α and C-RP. There was also a significant correlation observed between plasma A-FABP levels and clinical stage. On the other hand, no correlation was found between plasma levels of TNF-α or C-RP and clinical stage. The three biomarkers were not correlated with other paramters like patient's age, sex, BMI or smoking status. Conclusions: The findings in the present study suggested elevated levels of A-FABP, TNF-α and CRP in HNSCC patients before treatment that significantly decreased after treatment. Higher plasma A-FABP is associated with clinical stage and risk of HNSCC.



[1]  Rezende TMB, de Souza FM, Franco OL. Head and neck cancer. Cancer 2010; 116:4914-25.
[2]  Choi S, Myers JN. Molecular pathogenesis of oral squamous cellcarcinoma: implications for therapy. J Dent Res 2008; 87: 14-32.
[3]  Sotiriou CA, Lothaire PB, Dequanter DB, Cardoso FA, Awada AA. Molecular profiling of head and neck tumors.Curr Opin Oncol 2004;16:211-4.
[4]  Cairns RA, Harris IS, Mak TW. Regulation of cancer cellmetabolism. Nat Rev Cancer 2011:11:85-95.
[5]  Ward PS , Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012:21:297-308.
Show More References
[6]  Haunerland NH. Spener F. Fatty acid-binding proteins: insights from genetic manipulations. Prog Lipid Res 2004;43:328-49.
[7]  Fang LY, Wong TY, Chiang WF, Chen YL. Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J Oral Pathol Med 2010;39: 342-8.
[8]  Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489-503.
[9]  Smathers RL, Petersen DR. The human fatty-acid binding protein family: evolutionary divergences and functions. Hum Genomics 2011;5:170-191.
[10]  Pries R, Thiel A, Brocks C, Wollenberg B. Secretion of tumor-promoting and immune suppresive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo 2006; 20:45-8.
[11]  Lathers DM, Young MR. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of head and neck. Cytokine 2004; 25: 220-8.
[12]  Bellone G, Smirne C, Mauri FA et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2005;11:1-15.
[13]  Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novelmechanism of action. Oncogene 2002;21:6071-81.
[14]  Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solidtumours. Lancet Oncol 2003;4:565-73
[15]  Pries R, Nitsch S, Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 2006; 6:1195-203.
[16]  Black S, Kushner I, SamolsD. C-reactive protein. J BiolChem 2004; 279: 48487-90.
[17]  Heikkila K, ebrahim S, lawlor Da. A systematic review of theassociation between circulating concentrations of C- reactive protein and cancer. J epidemiol Commun Health 2007;61:824-33.
[18]  Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. The American Joint Committee on Cancer: the 7th edition of AJCC cancer staging manual and the future of TNM.Ann SurgOncol 2010;17:1471-4.
[19]  Chin D, Boyle GM, Theile DR, Parsons PG,Coman WB. Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 2004; 57: 595-602.
[20]  Douglas WG, Tracy E, Tan D, Yu J, Hicks WL, Rigual NR, et al. Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res 2004; 2:585-93.
[21]  Lee D, Wada K, TaniguchiY, AL-Shareef H, Masuda T, UsamiY, et al. Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol Reports 2014; 31:1116-20.
[22]  Ohyama Y, Kawamoto Y, Chiba T, Kikuchi K, Sakashita H, Imai K. Differential expression of fatty acid-binding proteins and pathological implications in the progression of tongue carcinoma. Mol Clin Oncol. 2014;2:19-25.
[23]  Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat. 2010;119:367-7.
[24]  Smathers RL and Petersen DR: The human fattyacid binding protein family: evolutionary divergences and functions. Hum Genomics 2011:5: 17091.
[25]  Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17: 1498-503.
[26]  Schroeder F, Petrescu AD, Huang H,Atshaves BP, McIntosh AL, Martin GG, et al. Role of fatty acidbinding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids 2008;43:1-17.
[27]  Hashimoto T, Kusakabe T, Sugino T, Fukuda T, Watanabe K, Sato Y, et al. Expression of heart-type fatty acid-binding protein in human gastric carcinoma and its association with tumor aggressiveness, metastasis and poor prognosis. Pathobiology 2004; 71: 267-73.
[28]  Karakas SE, Almario RU, Kim K. Serum fatty acid binding protein4, free fatty acids, and metabolic risk markers. Metabolism 2009;58:1002-7.
[29]  Bonomi M, Patsias A, Posner M, Sikora A. The role of inflammation in head and neck cancer. Adv Exp Med Biol. 2014;816:107-27.
[30]  Peter F, Wittekindt C, Finkensieper M, Kiehntopf M, Guntinas-Lichius O. Prognostic impact of pretherapeutic Laboratory values in head and neck cancer patients. J Cancer Res Clin Oncol 2013;139:171-8.
[31]  Andersson BA, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, LöfgrenS, et al. Plasma tumor necrosis factor‑α and C‑reactive proteinas biomarker for survival in head and neck squamous cellcarcinoma. J Cancer Res Clin Oncol 2014;14:1592-8.
[32]  Brailo V, Vucicevic-Boras V, Lukac J, Biocina-Lukenda, Zilic-Alajbeg I, Milenovic A, et al. Salivary and serum Interleukin 1 beta, interleukin 6 and tumor necrosis factor Alpha in patients with leukoplakia and oral cancer. Med Oral Patol Oral Cir Bucal 2012;17:e10-5.
[33]  Green VL, Michno A, Greenman J, Stafford ND. Effect of treatment on systemic cytokines in head and neck squamous cell carcinoma patients. Results in Immunology 2012; 2:1-6.
[34]  Allin KH, Bojesen SE, Nordestgaard BG. Base line C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27: 2217-24.
[35]  Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, et al. Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol 2011;36: 147-53.
[36]  Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 2003;37: 1-24.
[37]  Oliveira KG,von Zeidler SV, Lamas AZ, dePodesta JR, Sena A, Souza ED, et al. Relationship of inflammatory markers and pain in patients with head and neck cancer prior to anticancer therapy. Braz J Med Biol Res 2014;47:600-4.
[38]  Khandavilli SD, Ceallaigh PO, Lloyd CJ et al. Serum C-reactive protein as a prognostic indicator in patients with oral Squamous cell carcinoma. Oral Oncol 2009;45: 912-4.
[39]  Chen HH, Wang HM, Fan KH, Lin CY, Yen TC, Liao CT, et al. Pretreatment Levels of C-Reactive Protein and Squamous Cell Carcinoma Antigen for Predicting the Aggressiveness of Pharyngolaryngeal Carcinoma. PLoS ONE 2013;8: e55327.
Show Less References


Tamoxifen-resistant Breast Cancer: Causes of resistance and Possible Management

1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA

2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

3Fifth year student, College of Pharmacy, Taif University, Taif, KSA

Journal of Cancer Research and Treatment. 2016, 4(3), 37-40
doi: 10.12691/jcrt-4-3-1
Copyright © 2016 Science and Education Publishing

Cite this paper:
Ahmed M. Kabel, Dania Altalhi, Hanan Alsharabi, Ola Qadi, Maram Ad khan. Tamoxifen-resistant Breast Cancer: Causes of resistance and Possible Management. Journal of Cancer Research and Treatment. 2016; 4(3):37-40. doi: 10.12691/jcrt-4-3-1.

Correspondence to: Ahmed  M. Kabel, Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA. Email:


Tamoxifen has been used for the systemic treatment of patients with breast cancer by block the action of estrogen is also used to lower a woman's chance of developing breast cancer if she has a high risk . Treatment success is primarily dependent on the presence of the estrogen receptor (ER) in the breast carcinoma. While about half of patients with advanced ER-positive disease immediately fail to respond to tamoxifen, in the responding patients the disease ultimately progresses to a resistant phenotype. The possible causes for intrinsic and acquired resistance have been attributed to the pharmacology of tamoxifen, alterations in the structure and function of the ER and the interactions with the tumor environment and genetic alterations in the tumor cells.



[1]  Kabel A.M., Elkhoely A.A. Ameliorative potential of fluoxetine/raloxifene combination on experimentally-induced breast cancer. Tissue and Cell 2016; 48(2):89-95.
[2]  McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002; 296:1642-1644.
[3]  Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009;9:631-643.
[4]  Kabel A.M., El Rashidy M.A., Omar M.S. Ameliorative Potential of Tamoxifen/Thymoquinone Combination in Patients with Breast Cancer: A Biochemical and Immunohistochemical Study. Cancer Med. Anticancer Drug. 2016; 1:102.
[5]  Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature. 2000; 406:747–752.
Show More References
[6]  Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61-70.
[7]  Britton D.J., Hutcheson I.R., Knowlden J.M., Barrow D., Giles M., McClelland R.A., Gee J.M., Nicholson R.I. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006;96:131-146.
[8]  Osborne C.K., Fuqua S.A. Mechanisms of tamoxifen resistance. Breast Cancer Res. Treat., 32: 49-55, 1994.
[9]  Osborne C.K., Jarman M., McCague R., Coronado E. B., Hilsenbeck S.G., Wakeling A. E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother. Pharmacol., 34: 89-95, 1994.
[10]  Gottardis M. M., Jordan V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988; 48: 5183-5187.
[11]  Legault-Poisson S., Jolivet J., Poisson R., Beretta-Piccoli M., Band P. R. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep. 1979; 63: 1839-1841.
[12]  Hoskins J.M., Carey L.A., McLeod H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 2009;9:576-586.
[13]  Yang X., Phillips D.L., Ferguson A.T., Nelson W.G., Herman J.G., Davidson N.E. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res. 2001;61:7025-7029.
[14]  Parl F.F. Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer. Pharmacogenomics J. 2003;3:251-253.
[15]  Weigel R.J., deConinck E.C. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res. 1993;53:3472-3474.
[16]  Ottaviano Y.L., Issa J.P., Parl F.F., Smith H.S., Baylin S.B., Davidson N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994;54:2552-2555.
[17]  Creighton C.J., Hilger A.M., Murthy S., Rae J.M., Chinnaiyan A.M., El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Res. 2006;66:3903-3911.
[18]  Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., Wong J., Allred D.C., Clark G.M., Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 2003; 95:353-361.
[19]  Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., Franklin R.A., McCubrey J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 2003;17:590-603.
[20]  Datta S.R., Brunet A., Greenberg M.E. Cellular survival: A play in three Akts. Genes Dev. 1999;13:2905-2927.
[21]  Angel P., Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta. 1991;1072:129-157.
[22]  Sommer S., Fuqua S.A. Estrogen receptor and breast cancer. Semin. Cancer Biol. 2001;11:339-352.
[23]  Smith C.L., Nawaz Z., O’Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 1997;11:657-666.
[24]  Jordan V.C., O’Malley B.W. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 2007;25:5815-5824.
[25]  Lydon J.P., O’Malley B.W. Minireview: Steroid receptor coactivator-3: A multifarious coregulator in mammary gland metastasis. Endocrinology. 2011;152:19-25.
[26]  Azorsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M., Meltzer P.S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997;277:965-968.
[27]  Murphy L.C., Simon S.L., Parkes A., Leygue E., Dotzlaw H., Snell L., Troup S., Adeyinka A., Watson P.H. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res. 2000;60:6266-6271.
[28]  List H.J., Reiter R., Singh B., Wellstein A., Riegel A.T. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res. Treat. 2001;68:21-28.
[29]  Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B., Pike J.W., McDonnell D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 1994;8:21-30.
[30]  Knowlden J.M., Hutcheson I.R., Barrow D., Gee J.M., Nicholson R.I. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology. 2005;146:4609-4618.
[31]  Arpino G., Wiechmann L., Osborne C.K., Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29:217-233.
[32]  Loi S., Sotiriou C., Haibe-Kains B., Lallemand F., Conus N.M., Piccart M.J., Speed T.P., McArthur G.A. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics 2009;2:37.
[33]  Iorio M.V., Casalini P., Piovan C., Braccioli L., Tagliabue E. Breast cancer and microRNAs: Therapeutic impact. Breast 2011;20:S63-S70.
[34]  Desta Z., Ward B.A., Soukhova N.V., Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 2004;310:1062-1075.
[35]  Kiyotani K., Mushiroda T., Nakamura Y., Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab. Pharmacokinet. 2012;27:122-131.
[36]  Hoskins J.M., Carey L.A., McLeod H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer. 2009;9:576-586.
[37]  Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 2003;348:529-537.
[38]  Trimarchi M.P., Mouangsavanh M.,HuangT.H. Cancer epigenetics: A perspective on the role of DNA methylation in acquired endocrine resistance. Chin. J. Cancer. 2011;30:749-756.
[39]  Raina D., Uchida Y., Kharbanda A., Rajabi H., Panchamoorthy G., Jin C., Kharbanda S., Scaltriti M., Baselga J., Kufe D. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene 2014; 33(26): 3422-3431.
Show Less References